Crosstalk between 5-HT2cR and PTEN signaling pathway in atypical antipsychotic-induced metabolic syndrome and cognitive dysfunction

Medical Hypotheses

Volumn 80, Issue 4, 2013, Pages 486-489

  Cai, Jun ^a   Yi, Zhenghui ^a   Lu, Weihong ^a   Fang, Yiru ^a   Zhang, Chen ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; GLYCOGEN SYNTHASE KINASE 3; INSULIN; OLANZAPINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SEROTONIN 2 RECEPTOR;

ARTICLE; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; COGNITIVE DEFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GLUCOSE TRANSPORT; INSULIN RESISTANCE; LEARNING; LONG TERM POTENTIATION; MEMORY; METABOLIC SYNDROME X; NERVE CELL PLASTICITY; NONHUMAN; OBESITY; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION;

ANTIPSYCHOTIC AGENTS; BRAIN; COGNITION DISORDERS; HUMANS; METABOLIC SYNDROME X; PTEN PHOSPHOHYDROLASE; RECEPTOR, SEROTONIN, 5-HT2C; SIGNAL TRANSDUCTION;

EID: 84875397285     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.01.012     Document Type: Article

References (41)

1. Zhang C., Li Z., Shao Y., Xie B., Du Y., Fang Y., et al. Association study of tryptophan hydroxylase-2 gene in schizophrenia and its clinical features in Chinese Han population. J Mol Neurosci 2011, 43:406-411.
2. Miyamoto S., Duncan G.E., Marx C.E., Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005, 10:79-104.
3. Correll C.U., Kane J.M., Manu P. Obesity and coronary risk in patients treated with second-generation antipsychotics. Eur Arch Psychiatry Clin Neurosci 2011, 261:417-423.
4. Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome a new worldwide definition. Lancet 2005, 366:1059-1062.
5. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005, 80:19-32.
6. Lindenmayer J.P., Khan A., Kaushik S., Thanju A., Praveen R., Hoffman L., et al. Relationship between metabolic syndrome and cognition in patients with schizophrenia. Schizophr Res. 2012, 142:171-176.
7. Vigen C.L., Mack W.J., Keefe R.S., Sano M., Sultzer D.L., Stroup T.S., et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry 2011, 168:831-839.
8. Bai Y.M., Chen T.T., Liou Y.J., Hong C.J., Tsai S.J. Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics. Schizophrenia Res 2011, 125:179-186.
9. Bonhaus D.W., Weinhardt K.K., Taylor M., Desouza A., Mcneeley P.M., Szczepanski K., et al. RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist. Neuropharmacology 1997, 36:621-629.
10. Tecott L.H., Sun L.M., Akana S.F., Strack A.M., Lowenstein D.H., Dallman M.F., et al. Eating disorder and epilepsy in mice lacking 5-Ht2c serotonin receptors. Nature 1995, 374:542-546.
11. Mulder H., Cohen D., Scheffer H., Gispen-de Wied C., Arends J., Wilmink F.W., et al. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia a replication study. J Clin Psychopharm 2009, 29:16-20.
12. Al-Janabi I., Arranz M.J., Blakemore A.I.F., Saiz P.A., Susce M.T., Glaser P.E.A., et al. Association study of serotonergic gene variants with antipsychotic-induced adverse reactions. Psychiat Genet 2009, 19:305-311.
13. Muller D.J., Kennedy J.L. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 2006, 7:863-887.
14. Poa N.R., Edgar P.F. Insulin resistance is associated with hypercortisolemia in polynesian patients treated with antipsychotic medication. Diabetes Care 2007, 30:1425-1429.
15. Houseknecht K.L., Robertson A.S., Zavadoski W., Gibbs E.M., Johnson D.E., Rollema H. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacol 2007, 32:289-297.
16. Frisardi V., Solfrizzi V., Capurso C., Imbimbo B.P., Vendemiale G., Seripa D., et al. Is insulin resistant brain state a central feature of the metabolic-cognitive syndrome?. J Alzheimers Dis 2010, 21:57-63.
17. Mu N., Zhu Y.X., Wang Y.M., Zhang H.Y., Xue F.X. Insulin resistance: a significant risk factor of endometrial cancer. Gynecol Oncol 2012, 125:751-757.
18. Kim B., Feldman E.L. Insulin resistance in the nervous system. Trends Endocrin Met 2012, 23:133-141.
19. Huang S.H., Czech M.P. The GLUT4 glucose transporter. Cell Metab 2007, 5:237-252.
20. Sesti G. Pathophysiology of insulin resistance. Best Pract Res Clin Endocrinol Metab 2006, 20:665-679.
21. Boura-Halfon S., Zick Y. Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab 2009, 296:E581-591.
22. Ueki K., Yballe C.M., Brachmann S.M., Vicent D., Watt J.M., Kahn C.R., et al. Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase. Proc Natl Acad Sci USA 2002, 99:419-424.
23. Asano T., Fujishiro M., Kushiyama A., Nakatsu Y., Yoneda M., Kamata H., et al. Role of phosphatidylinositol 3-kinase activation on insulin action and its alteration in diabetic conditions. Biol Pharm Bull 2007, 30:1610-1616.
24. Hay N. Akt isoforms and glucose homeostasis- the leptin connection. Trends Endocrinol Metab 2011, 22:66-73.
25. Gonzalez E., McGraw T.E. Insulin-modulated Akt subcellular localization determines Akt isoform-specific signaling. Proc Natl Acad Sci U S A 2009, 106:7004-7009.
26. Bouskila M., Hirshman M.F., Jensen J., Goodyear L.J., Sakamoto K. Insulin promotes glycogen synthesis in the absence of GSK3 phosphorylation in skeletal muscle. Am J Physiol Endocrinol Metab 2008, 294:E28-35.
27. Kockeritz L., Doble B., Patel S., Woodgett J.R. Glycogen synthase kinase-3-an overview of an over-achieving protein kinase. Curr Drug Targets 2006, 7:1377-1388.
28. Okumura N., Yoshida H., Kitagishi Y., Murakami M., Nishimura Y., Matsuda S. PI3K/AKT/PTEN signaling as a molecular target in leukemia angiogenesis. Adv Hematol 2012, 2012:843085.
29. Downes C.P., Perera N., Ross S., Leslie N.R. Substrate specificity and acute regulation of the tumour suppressor phosphatase PTEN. Biochem Soc Symp 2007, 69-80.
30. Chalhoub N., Baker S.J. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 2009, 4:127-150.
31. Park K.K., Liu K., Hu Y., Kanter J.L., He Z. PTEN/mTOR and axon regeneration. Exp Neurol 2010, 223:45-50.
32. Sperow M., Berry R.B., Bayazitov I.T., Zhu G., Baker S.J., Zakharenko S.S. Phosphatase and tensin homologue (PTEN) regulates synaptic plasticity independently of its effect on neuronal morphology and migration. J Physiol 2012, 590:777-792.
33. Mayford M., Siegelbaum S.A., Kandel E.R. Synapses and memory storage. Cold Spring Harb Perspect Biol 2012, 4.
34. Bliss T.V., Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol 1973, 232:331-356.
35. Matynia A., Kushner S.A., Silva A.J. Genetic approaches to molecular and cellular cognition: a focus on LTP and learning and memory. Annu Rev Genet 2002, 36:687-720.
36. Ghiglieri V., Pendolino V., Bagetta V., Sgobio C., Calabresi P., Picconi B. MTOR inhibitor rapamycin suppresses striatal post-ischemic LTP. Exp Neurol 2010, 226:328-331.
37. Sui L., Wang J., Li B.M. Role of the phosphoinositide 3-kinase-Akt-mammalian target of the rapamycin signaling pathway in long-term potentiation and trace fear conditioning memory in rat medial prefrontal cortex. Learn Mem 2008, 15:762-776.
38. Kumar V., Zhang M.X., Swank M.W., Kunz J., Wu G.Y. Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways. J Neurosci 2005, 25:11288-11299.
39. Blair P.J., Harvey J. PTEN: a new player controlling structural and functional synaptic plasticity. J Physiol 2012, 590:1017.
40. Moult P.R., Cross A., Santos S.D., Carvalho A.L., Lindsay Y., Connolly C.N., et al. Leptin regulates AMPA receptor trafficking via PTEN inhibition. J Neurosci 2010, 30:4088-4101.
41. Ji S.P., Zhang Y., Van Cleemput J., Jiang W., Liao M., Li L., et al. Disruption of PTEN coupling with 5-HT2C receptors suppresses behavioral responses induced by drugs of abuse. Nat Med 2006, 12:324-329.